Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
Follow SCLX
Scilex Holding Company (SCLX) EV/Sales
As of 16 October 2026, Scilex Holding Company (SCLX) trades at a EV/Sales of 3.2×. Over the past ten years it has ranged from 0.0× (December 2022) to 31.5× (April 2023); the current reading is higher than 45% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.2× | 133.40% |
| FY2024 | 2.2× | (62.24%) |
| FY2023 | 5.9× | (50.03%) |
| FY2022 | 11.8× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.3× | 35.16% |
| Mar 2026 | 3.2× | (39.18%) |
| Dec 2025 | 5.2× | 11.53% |
| Sep 2025 | 4.7× | 159.98% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC compare | −0.3× |
| MIRA MIRA Pharmaceuticals, Inc. compare | n/m |
| MDCX Medicus Pharma Ltd compare | n/m |
| NSRX Nasus Pharma Ltd. compare | n/m |
| GRFS Grifols, S.A. compare | 1.8× |
| OGN Organon & Co. compare | 1.8× |
| SNY Sanofi compare | 2.0× |
| SCLX Scilex Holding Company | 3.2× |
| BIIB Biogen Inc. compare | 4.0× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)